Get the Stockscreener App
23.97
2.70%
+0.63
After Hours:
23.52
-0.45
-1.88%
Schrodinger Inc stock is currently priced at $23.97, with a 24-hour trading volume of 706.20K.
It has seen a +2.70% increased in the last 24 hours and a -6.55% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $23.26 pivot point. If it approaches the $24.30 resistance level, significant changes may occur.
Previous Close:
$23.34
Open:
$23.6
24h Volume:
706.20K
Market Cap:
$1.74B
Revenue:
$216.67M
Net Income/Loss:
$40.72M
P/E Ratio:
42.80
EPS:
0.56
Net Cash Flow:
$-150.14M
1W Performance:
-1.32%
1M Performance:
-6.55%
6M Performance:
+7.73%
1Y Performance:
-15.69%
1D Range:
$23.36
$24.27
52W Range:
$20.76
$59.24
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
212 295 5800
Address
120 West 45th Street, 17th Floor, New York, NY
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Billionaire Bill Gates Has 35% of His Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks: Are They No-Brainer Buys?
The Motley Fool
Critical Insights From Schrodinger Analyst Ratings: What You Need To Know
Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Okta Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket
Benzinga
Shoals Technologies Posts Weak Q4 Results, Joins Butterfly Network, Schrödinger And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga
Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks Investment Research
Schrodinger Inc Stock (SDGR) Financials Data
Schrodinger Inc (SDGR) Revenue 2024
SDGR reported a revenue (TTM) of $216.67 million for the quarter ending December 31, 2023, a +19.73% rise year-over-year.
Schrodinger Inc (SDGR) Net Income 2024
SDGR net income (TTM) was $40.72 million for the quarter ending December 31, 2023, a +127.29% increase year-over-year.
Schrodinger Inc (SDGR) Cash Flow 2024
SDGR recorded a free cash flow (TTM) of -$150.14 million for the quarter ending December 31, 2023, a -17.57% decrease year-over-year.
Schrodinger Inc (SDGR) Earnings per Share 2024
SDGR earnings per share (TTM) was $0.52 for the quarter ending December 31, 2023, a +124.76% growth year-over-year.
About Schrodinger Inc
Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. It segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; and Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery. The company was founded in 1990 and is based in New York.
1.66%
1.42%
Cap:
|
Volume (24h):